The treatment effect on peripheral B cell markers in antibody positive myasthenia gravis patients

YILMAZ V., TÜZÜN E., DURMUŞ TEKÇE H., Oflazer P., Aysal F., Parman Y., ...Daha Fazla

JOURNAL OF NEUROIMMUNOLOGY, cilt.349, 2020 (SCI-Expanded) identifier identifier identifier

  • Yayın Türü: Makale / Tam Makale
  • Cilt numarası: 349
  • Basım Tarihi: 2020
  • Doi Numarası: 10.1016/j.jneuroim.2020.577402
  • Dergi Adı: JOURNAL OF NEUROIMMUNOLOGY
  • Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus, Academic Search Premier, BIOSIS, CAB Abstracts, Chemical Abstracts Core, EMBASE, MEDLINE, Psycinfo, Veterinary Science Database
  • Anahtar Kelimeler: B cell, Myasthenia gravis, Immunosuppressive effect, BAFF, CD38, ACTIVATING FACTOR, BAFF, APRIL, NAIVE, SERUM, MUSK
  • İstanbul Üniversitesi Adresli: Evet

Özet

B cells play a major role in the pathophysiology of myasthenia gravis (MG) with their ability to produce disease specific, pathogenic antibodies. However, their status during disease development and follow-up stages of the disease in the peripheral blood may need further studies to determine useful markers. In this study, we aimed to detect B cell associated factors concerning immunosuppressive treatment in generalized non-thymomatous MG patients. Although CD19(+) B cell distribution did not vary among disease subgroups, expressions of both CD38 and BAFFR were altered on B cells in MG patients under immunosuppressive therapy. Serum levels of BAFF were elevated in untreated MG patients as compared to treated MG patients and healthy controls. B cell activation factors may show profound alterations due to immunosuppression.